Advertisement
AMGN or LLY or PFE
AMGN in upward trend: 10-day moving average moved above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 45 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 24, 2026. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in 27 of 47 cases over the following month. The odds of a continued upward trend are 57%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 189 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 151 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMGN moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 26 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.318) is normal, around the industry mean (-2.730). P/E Ratio (27.081) is within average values for comparable stocks, (21.349). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.040) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
Aroon Indicator for LLY shows an upward move is likely
LLY's Aroon Indicator triggered a bullish signal on October 19, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 297 similar instances where the Aroon Indicator showed a similar pattern. In 230 of the 297 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 51 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for LLY just turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 30 of 45 cases over the following month. The odds of a continued upward trend are 67%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +4.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The 10-day RSI Indicator for LLY moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 21 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
LLY broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (33.505) is slightly higher than the industry average of (-2.730). P/E Ratio (42.662) is within average values for comparable stocks, (21.349). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.040) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
PFE in +1.27% Uptrend, growing for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFE advanced for three days, in 149 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PFE as a result. In 41 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 47%.
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 17 of 43 cases over the following month. The odds of a continued upward trend are 40%.
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 14 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
PFE broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.009) is normal, around the industry mean (-2.730). P/E Ratio (39.000) is within average values for comparable stocks, (21.349). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.057) settles around the average of (0.040) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
AMGN | LLY | PFE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 80 | 34 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 87 Overvalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 5 | 7 | 100 | |
SMR RATING 1..100 | 15 | 14 | 83 | |
PRICE GROWTH RATING 1..100 | 8 | 6 | 15 | |
P/E GROWTH RATING 1..100 | 26 | 65 | 3 | |
SEASONALITY SCORE 1..100 | 75 | 29 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (80) in the Biotechnology industry is in the same range as LLY (87) in the Pharmaceuticals Major industry, and is in the same range as PFE (93) in the Pharmaceuticals Major industry. This means that AMGN's stock grew similarly to LLY’s and similarly to PFE’s over the last 12 months.
AMGN's Profit vs Risk Rating (5) in the Biotechnology industry is in the same range as LLY (7) in the Pharmaceuticals Major industry, and is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that AMGN's stock grew similarly to LLY’s and significantly faster than PFE’s over the last 12 months.
LLY's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as AMGN (15) in the Biotechnology industry, and is significantly better than the same rating for PFE (83) in the Pharmaceuticals Major industry. This means that LLY's stock grew similarly to AMGN’s and significantly faster than PFE’s over the last 12 months.
LLY's Price Growth Rating (6) in the Pharmaceuticals Major industry is in the same range as AMGN (8) in the Biotechnology industry, and is in the same range as PFE (15) in the Pharmaceuticals Major industry. This means that LLY's stock grew similarly to AMGN’s and similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (3) in the Pharmaceuticals Major industry is in the same range as AMGN (26) in the Biotechnology industry, and is somewhat better than the same rating for LLY (65) in the Pharmaceuticals Major industry. This means that PFE's stock grew similarly to AMGN’s and somewhat faster than LLY’s over the last 12 months.
| AMGN | LLY | PFE | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | 2 days ago 62% | 2 days ago 52% |
| Stochastic ODDS (%) | 2 days ago 47% | 2 days ago 60% | 2 days ago 61% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 62% | 2 days ago 47% |
| MACD ODDS (%) | 2 days ago 57% | 2 days ago 67% | 2 days ago 40% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 69% | 2 days ago 54% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 69% | 2 days ago 49% |
| Advances ODDS (%) | 10 days ago 61% | 9 days ago 70% | 9 days ago 54% |
| Declines ODDS (%) | 6 days ago 47% | 23 days ago 55% | 20 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 40% | 2 days ago 53% | 2 days ago 52% |
| Aroon ODDS (%) | 2 days ago 56% | 2 days ago 77% | 2 days ago 66% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while LLY’s FA Score has 3 green FA rating(s), and PFE’s FA Score reflects 2 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- LLY’s FA Score: 3 green, 2 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while LLY’s TA Score has 6 bullish TA indicator(s), and PFE’s TA Score reflects 3 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 4 bearish.
- LLY’s TA Score: 6 bullish, 4 bearish.
- PFE’s TA Score: 3 bullish, 5 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +1.57% price change this week, while LLY (@Pharmaceuticals: Major) price change was +1.31% , and PFE (@Pharmaceuticals: Major) price fluctuated +1.52% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.08%. For the same industry, the average monthly price growth was -4.91%, and the average quarterly price growth was +4.21%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
LLY is expected to report earnings on Oct 29, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.08% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | -1.79% | ||
| PFE - AMGN | 51% Loosely correlated | -1.28% | ||
| GILD - AMGN | 48% Loosely correlated | -0.73% | ||
| ABBV - AMGN | 48% Loosely correlated | +0.16% | ||
| BIIB - AMGN | 47% Loosely correlated | -1.24% | ||
| MRK - AMGN | 47% Loosely correlated | -1.34% | ||
More | ||||
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with JNJ. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then JNJ could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -1.28% | ||
| BMY - PFE | 57% Loosely correlated | -2.41% | ||
| AMGN - PFE | 52% Loosely correlated | -1.79% | ||
| NVS - PFE | 49% Loosely correlated | -3.30% | ||
| BIIB - PFE | 48% Loosely correlated | -1.24% | ||
| SNY - PFE | 47% Loosely correlated | -0.86% | ||
More | ||||